London, UK (PRWEB) September 01, 2014
Currently, scientists continue to face fundamental challenges in developing more effective treatments for Alzheimer's disease (AD), which reflects their poor understanding of the disease. Uncertainties also exist regarding the diagnosis of the disease, especially in its early stages, and, hence, the lack of appropriate diagnostic tests. In 2014, after decades that have witnessed a range of the greatest breakthroughs in the medicine world, there are still no disease-modifying therapies for AD and those treatments that do exist deliver only small, and usually short-term, benefits for patients. Recently, much attention has been paid to fundamental research and AD biomarker discovery, as well as to the identification of novel treatment strategies. Some of the major advancements in the field have been provided by such imaging methods as PET and MRI, which have assisted in mapping the time-course of AD as well as changes pertaining to molecules like Tau and amyloid-beta (Abeta). Studies have also profiled cerebrospinal fluid (CSF) biomarkers, specifically with respect to Abeta. Nevertheless, whilst these methods are key to AD research, both are expensive and complex and hence are not readily available to much wider patient populations.
Until now, 4 medications for AD as well as 103 in the drug-development pipeline have been approved by FDA. Of these, 11, 41, 30 and 21 candidates are in Phase III, Phase II, Phase I and pre-clinical trials, respectively. An analysis of these in terms of molecule types demonstrates that small molecules make up the largest group (70% all in all), with antibodies (8%), vaccines (7%) and others (15%) following in. In terms of the major pharmacological targeting strategies, 34 (32%) of candidates are targeted around the Abeta.
New research study “Early-Stage Minimally-Invasive Biomarkers in Alzheimer's Disease: A Comprehensive Analysis and Market Study of New Developments and Opportunities, 2014” worked out by Biopharm Reports is now available at MarketPublishers.com.
Title: Early-Stage Minimally-Invasive Biomarkers in Alzheimer's Disease: A Comprehensive Analysis and Market Study of New Developments and Opportunities, 2014
Published: August, 2014
Price: US$ 3,071.00
The research report offers an exhaustive examination and detailed market analysis of novel developments with respect to minimally invasive biomarkers for early diagnosis of Alzheimer's disease, which are functionally analysed along with current AD drugs and candidates in the AD drug-development pipeline, and applicable commercial diagnostic tests for the disease.
- Deep review of more than 270 candidate biomarkers in AD.
- A focused investigation of early stage biomarkers identified in studies of patients with AD.
- Coverage of more than 35 areas of the AD biomarker market landscape.
- Early stage disease, anticipated conversion to AD and the progression of the disease.
- Validated clinical trials, citing diagnostic specificity, sensitivity and accuracy.
- AD biomarker identification utilising blood, urine, saliva, and other minimally invasive techniques.
- In-depth overview of the latest findings and innovative developments.
- Functional review of AD drugs and drug candidates in development.
- Prospective opportunities of the companion diagnostics market.
- Detailed review of the existing AD drug development pipeline as well as companies with the disease related diagnostics tests, developments and platforms with respect to minimally invasive approaches and capabilities.
- Commercial assessment of relevant minimally invasive diagnostic tests and companies.
More new research studies by the publisher can be found at Biopharm Reports page.